Cardiology 2015: Status On Pharmacology News, Debates & Novelties
|
|
- Melanie Walters
- 5 years ago
- Views:
Transcription
1 Cardiology 2015: Status On Pharmacology News, Debates & Novelties George D. Dangas, MD, FESC, FACC Professor of Medicine (Cardiovascular Disease) Icahn School of Medicine at Mount Sinai Zena & Michael A. Weiner Cardiovascular Institute New York, USA
2 TAVR 2015: Current Status On Pharmacology
3 TAVR complications TAVR has produced similar result to surgery and superior to conservative management of severe AS Yet, it possesses its own range of complications, dominated by bleeding and vascular events Limiting peri-procedure anticoagulation might appear as an option if there was no fear of thrombosis
4 The Problem DWI (MRI) Following AVR Showing Silent Stroke 4
5 Thromboembolism from the valve site Thromboemboli from the bioprosthesis before endothelialization completes. Aggregation of platelet and fibrin has been known to occur on valve leaflet within a few hours after implantation. Tay et al, JACC Cardiovasc Interv 2011
6 Expression of Tissue Factor in aortic valve leaflets of varying status normal sclerotic stenotic Maréchaux et al. Cardiovasc Pathol 2009
7 Tissue Factor and Thrombin co-localize with calcification in patients with Aortic Stenosis (n=52) Breyne et al. Atherosclerosis 2010
8 Endothelization of the Valve Stent Long-term data from bioprosthetic valve studies indicate that neointimal tissue growth and endothelization of the valve stent occur about 3 months after implantation, when the risk of stroke shows a corresponding reduction 1. Histopathological studies of the CoreValve apparatus show a similar timeline for the endothelization of the transcatheter device 2. Thus, the critical period for devicerelated thromboembolic events is likely between 24 h and 3 months after TAVR. 1. Merie et al JAMA Noble et al EuroIntervention 2009
9 Reduced leaflet motion was observed in all valve types including surgical bioprostheses Corevalve Portico Sapien Perimount surgical valve Diastole Systole
10 Risk of ischaemic and bleeding complications after TAVR Nijenhuis VJ et al. Thromb Haemost 2015
11 Standard antithrombotic therapy during TAVR Anticoagulant therapy: UFH +/- protamine at the end of the procedure Coumadin+/-ASA or DAPT for afib+tavr Antiplatelet therapy: aspirin and/or clopidogrel pre-procedure at operators discretion (PARTNER Design) Nothing standardized
12 Dual Versus Single Antiplatelet Therapy in Patients Undergoing TAVR: A Systematic Review and Meta-Analysis No differences in stroke between DAPT and SAPT at 30 days Higher risk of bleeding with DAPT at 30 days No differences in mortality between DAPT and SAPT at 30 days Heart, Lung and Circulation (2014) xx, 1 8
13 Lefevre T, et al LBCT abstract Dangas GD et al, BRAVO3 Investigators paper submitted The Randomized Multicenter BRAVO-3 trial August 2015 Update: Complete - LBCT at TCT-2015 on October patients undergoing transfemoral TAVR standard dosing of bivalirudin R Heparin Possible reversal with Protamine is allowed CO- PRIMARY EP MAJOR BLEEDING at 48hrs & NACE at 30-days
14 GALILEO Global study comparing a rivaroxaban-based antithrombotic strategy to an antiplatelet-based strategy after transcatheter aortic valve replacement to Optimize clinical outcomes George D. Dangas, MD, FACC, FESC & Stephan Windecker, MD, FESC
15 Rivaroxaban Rivaroxaban is an oral anticoagulant that directly and selectively inhibits factor Xa. Factor Xa initiates the final common pathway of the coagulation cascade and results in the formation of thrombin, which catalyzes additional coagulation-related reactions and promotes platelet activation. Rivaroxaban In the ATLAS-ACS 2-TIMI 51 Trial, 2.5 mg Bid and 5 mg Bid Rivaroxaban decreased the risk of death, MI or stroke in patients with a recent acute coronary syndrome 1. The risk of fatal bleeding was increased only in the 5 mg arm. In the ROCKET-AF Trial, 20 mg Qd was noninferior to Warfarin in reducing the risk of stroke or systemic embolism and was associated with a reduction in risk of intracranial or fatal bleeding Patel et al - N engl j med 365;10 2. Mega et al - N engl j med 366;1
16 GALILEO Study Flow Diagram
17 Summary The balance between ischemic and bleeding events in TAVR patients is challenging With a more standardized antithrombotic protocols, a more meaningful assessment of CVE prevention can be made The optimal antithrombotic regimen (antiplatelet and/or anticoagulant) during and after TAVI has to be established Anticoagulation plus a oral antiplatelet appears appealing but still not assessed. Randomized, prospective trials of Embolic Protection Devices to commence soon with a multi-center, multi-country design
18 Longer DAPT is associated with lower risk of Stent Thrombosis and Myocardial Infarction Giustino,.. Dangas; JACC 2015
19 32,135 patients 10 trials Mean weighted follow-up time among all 10 RCTs was 19.6 months. Mean weighted exposure time to antiplatelet therapy within the S-DAPT and L-DAPT groups was 8.5 and 23.2 months, respectively. Giustino,.. Dangas; JACC 2015
20 Shorter DAPT is associated with lower risk of Clinically Significant Bleeding and All-Cause Mortality *CSB defined as a BARC 3 or 5, TIMI major or minor, GUSTO moderate or severe or STEEPLE major Giustino, Dangas; JACC 2015
21 Trade-Off Between Stent Thrombosis and Bleeding Over Time Incidence rates and standardized incidence risk difference for Stent Thrombosis and Clinically Significant Bleeding per 100 person/year between S-DAPT and L-DAPT For every ST event averted with L-DAPT, approximately 2.1 extra CSB events are estimated to occur ( ST / 0.21 CSB per 100 person / year). *CSB defined as a BARC 3 or 5, TIMI major or minor, GUSTO moderate or severe or STEEPLE major Giustino,.. Dangas; JACC 2015
22 First- Versus Second-Generation DES and risk for Stent Thrombosis.. Where is the difference? 1 st -generation DES 2 nd -generation DES SES 13 months PES 11 months ZES 3 months EES 6 months Representative Images of 2 nd - vs. 1 st -generation DES in Human Coronary Arteries
23 Risk of ST with 1 st - and 2 nd -Generation Drug-Eluting Stents According to Duration of Dual Antiplatelet Therapy Giustino, Dangas; JACC 2015
24 Novelties 2015PCSK9: Proprotein Convertase Subtilisin-Kexin Type 9 PCSK9 plays a pivotal role in LDL cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL receptor (LDL-R) promotes the degradation of the LDL-R prevents it from recycling to the membrane controls whether internalized LDL-R is recycled or catabolized may also influence Apo B synthesis and triglyceride secretion Serine protease predominantly expressed by the liver and intestine In PCSK9 human population studies: Gain-of-function mutations result in hypercholesterolemia Loss-of-function mutations associated with low LDL-C and low prevalence of CHD events Lambert et al Atherosclerosis 2009;203:1 7 Lambert et al J Lipid Res 2012;53:
25 The Role of PCSK9 in the Regulation of LDL Receptor Expression For illustration purposes only 25
26 Impact of an PCSK9 synthesis inhibition on LDL Receptor Expression For illustration purposes only 26
27 LDL-C values achieved vs. study time-points (ITT analysis). Percentages above Weeks 12 and 24 data points indicate LS mean (SE) percent change from baseline. Values above Weeks 24 and 52 indicate achieved LDL-C. In patients at high cardiovascular risk with inadequately controlled LDL-C, alirocumab achieved significantly greater reductions in LDL-C compared with ezetimibe, with a similar safety profile. European Heart Journal doi: /eurheartj/ehv028
28 Randomization 2:2:1:1 End of Study GAUSS-2 Study Design Screening and placebo run-in period Fasting LDL-C 5 10 days before randomization Subcutaneous injection of placebo Evolocumab 140 mg SC Q2W + Placebo PO QD N = 103 Evolocumab 420 mg SC QM + Placebo PO QD N = 102 Placebo SC Q2W + Ezetimibe 10 mg PO QD N = 51 Placebo SC QM + Ezetimibe 10 mg PO QD N = 51 Maximum 6 weeks Time point Evolocumab or Placebo SC Q2W Day 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Week 14 Evolocumab or Placebo SC QM Prior intolerance to 2 statins: LDL-C above NCEP ATP III risk category goal : Weekly dose 7 times the smallest available tablet strength or less Stroes et al J Am Coll Cardiol. 2014;63(23): QM EOS Q2W EOS*
29 Mean Percent Change in LDL-C from Baseline GAUSS-2: Evolocumab 140 mg Q2W LDL-C Response % % Study drug administration Biweekly SC Number of subjects: BL Day 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Study Week 1: Ezetimibe (N = 51) 2: Evolocumab 140 mg Q2W (N = 103) BL, baseline. Vertical lines represent the standard error around the mean. Plot is based on observed data with no imputation for missing values. P values are multiplicity adjusted. Stroes et al J Am Coll Cardiol. 2014;63(23):
30 Mean Percent Change in LDL-C from Baseline GAUSS-2: Evolocumab 420 mg Q4W LDL-C Response % Number of subjects: % Study drug administration Monthly SC BL Day 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Study Week 1: Ezetimibe (N = 51) 2: Evolocumab 420 mg QM (N = 102) BL, baseline. Vertical lines represent the standard error around the mean. Plot is based on observed data with no imputation for missing values. P values are multiplicity adjusted. Stroes et al J Am Coll Cardiol. 2014;63(23):
31 Randomization 2:2:1:1 End of Study GAUSS-2 Study Design Screening and placebo run-in period Fasting LDL-C 5 10 days before randomization Subcutaneous injection of placebo Evolocumab 140 mg SC Q2W + Placebo PO QD N = 103 Evolocumab 420 mg SC QM + Placebo PO QD N = 102 Placebo SC Q2W + Ezetimibe 10 mg PO QD N = 51 Placebo SC QM + Ezetimibe 10 mg PO QD N = 51 Maximum 6 weeks Time point Evolocumab or Placebo SC Q2W Evolocumab or Placebo SC QM Day 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Week 14 Prior intolerance to 2 statins: LDL-C above NCEP ATP III risk category goal : Weekly dose 7 times the smallest available tablet strength or less Stroes et al J Am Coll Cardiol. 2014;63(23): QM EOS Q2W EOS*
32 Mean Percent Change in LDL-C from Baseline GAUSS-2: Evolocumab 140 mg Q2W LDL-C Response % % Number of subjects: Study drug administration Biweekly SC BL Day 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Study Week 1: Ezetimibe (N = 51) 2: Evolocumab 140 mg Q2W (N = 103) BL, baseline. Vertical lines represent the standard error around the mean. Plot is based on observed data with no imputation for missing values. P values are multiplicity adjusted Ṡtroes et al J Am Coll Cardiol. 2014;63(23):
33 Mean Percent Change in LDL-C from Baseline GAUSS-2: Evolocumab 420 mg Q4W LDL-C Response % Number of subjects: % Study drug administration Monthly SC BL Day 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Study Week 1: Ezetimibe (N = 51) 2: Evolocumab 420 mg QM (N = 102) BL, baseline. Vertical lines represent the standard error around the mean. Plot is based on observed data with no imputation for missing values. P values are multiplicity adjusted. Stroes et al J Am Coll Cardiol. 2014;63(23):
34 Proportion of Patients Achieving LDL-C Target Goal at Week 12, n (%) GAUSS-2: LDL-C Goal Achievement (92%) 7 (70%) at Week (80%) 29 (91%) 36 (77%) 40 (76%) (0%) 0 (0%) Lower Risk* < 160 mg/dl 1 (8%) 3 (20%) Moderately High Risk < 130 mg/dl 2 (7%) 1 (4%) High Risk < 100 mg/dl Ezetimibe QD + PBO Q2W Ezetimibe QD + PBO QM Evolocumab 140 mg Q2W + PBO QD Evolocumab 420 mg QM + PBO QD *Combination of NCEP ATP IIII moderate and low risk categories. Rate based on subjects with observed values at Week 12 and LDL-C above target goal at baseline Stroes et al J Am Coll Cardiol. 2014;63(23):
35 Post-hoc Adjudicated Cardiovascular TEAEs (Same as primary endpoint of ongoing ODYSSEY OUTCOMES trial ) Safety Analysis (at least 52 weeks for all patients continuing treatment, including 607 patients who completed W78 visit) % (n) of patients All patients on background of max tolerated statin ± other lipid-lowering therapy Alirocumab (n=1550) Placebo (n=788) CV events confirmed by adjudication 1.4% (22) 3.0% (24) CHD death 0.2% (3) 0.8% (6) Non-fatal MI 0.7% (11) 2.2% (17) Fatal + non-fatal ischaemic stroke 0.5% (8) 0.3% (2) Unstable angina requiring hospitalisation 0 0.1% (1) Patients are censored at the end of TEAE period (last injection of study treatment + 70 days). Primary endpoint for the ODYSSEY OUTCOMES trial: CHD death, Non-fatal MI, Fatal and non-fatal ischemic stroke, Unstable angina requiring hospitalisation. Unstable angina requiring hospitalisation is limited to the UA events with definite evidence of progression of the ischemic condition (strict criteria). Robinson J et al ESC hotline session Barcelona Aug 31, 2014
36 Cumulative probability of event Post-hoc Adjudicated Cardiovascular TEAEs Safety Analysis (at least 52 weeks for all patients in ongoing study) Kaplan-Meier Estimates for Time to First Adjudicated Major CV Event Safety Analysis (at least 52 weeks for all patients continuing treatment, including 607 patients who completed W78 visit) Placebo + max-tolerated statin ± other LLT Alirocumab + max-tolerated statin ± other LLT Cox model analysis: HR=0.46 (95% CI: 0.26 to 0.82) Nominal p-value = <0.01 Mean treatment duration: 65 weeks No. at Risk Placebo Alirocumab Weeks Primary endpoint for the ODYSSEY OUTCOMES trial: CHD death, Non-fatal MI, Fatal and non-fatal ischemic stroke, Unstable angina requiring hospitalisation. LLT, lipid-lowering therapy Robinson J et al ESC hotline session Barcelona Aug 31,
37 Evolocumab (AMG 145) Alirocumab (SAR /REGN727) Bococizumab (RN 316) Sponsor Amgen Sanofi / Regeneron Pfizer Trial FOURIER ODYSSEY Outcomes SPIRE I SPIRE II Sample size 22,500 18,000 12,000 6,300 Patients MI, stroke or PAD 4-52 wks post-acs High risk of CV event Statin Atorva 20 mg or equiv Evid-based med Rx Lipid-lowering Rx LDL-C mg/dl(mmol/l) PCSK9 Inhibitor Cardiovascular Outcomes Trials 70 ( 1.8) 70 ( 1.8) ( ) 100 ( 2.6) PCSK9i Dosing Q2W or Q4W Q2W Q2W Endpoint 1 : CV death, MI, stroke, revasc or hosp for UA, Key 2 : CV death, MI, or stroke CHD death, MI, ischemic stroke, or hosp for UA CV death, MI, stroke, or urgent revasc Completion 12/2017 1/2018 8/2017
38 INTERVENTIONAL PHARMACOLOGY 2015 Conclusions TAVR is expanding Dedicated pharmacological studies underway DAPT debate will continue as the academic rivalry (and stent type) drives the 2 different opinion PCSK-9 inhibitors will be a game changer for all vascular beds
Adjunctive Pharmacotherapy: Current Landscape for Patients Post TAVR
Adjunctive Pharmacotherapy: Current Landscape for Patients Post TAVR George D. Dangas, MD, FACC, FAHA, FESC, MSCAI Professor of Medicine & Surgery Icahn School of Medicine at Mount Sinai The Mount Sinai
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationMarch 30, 2014, Joint ACC/JAMA Late-breaking Clinical Trials Session 402 American College of Cardiology, Washington DC
A Phase 3 Double-blind, Randomized Study to Assess Safety and Efficacy of Evolocumab (AMG 145) in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of Statin Erik Stroes 1, David Colquhoun
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationPCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH
PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH Presented by: Michael J. Blaha November 16, 2017 1 Financial Disclosures Grants: Amgen Foundation, Aetna Foundation Advisory Boards: Amgen,
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationAntithrombotic. DAPT or OAC?
Antithrombotic treatment after TAVI: DAPT or OAC? Striking the right balance. Pascal Vranckx MD, PhD. Hartcentrum Hasselt, Belgium. Disclosure of Interest Pascal Vranckx has the following potential conflicts
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationAntithrombotic Rx in the Setting of TAVI
Antithrombotic Rx in the Setting of TAVI George D. Dangas, MD, PhD, FESC, MSCAI Professor of Medicine & Surgery Icahn School of Medicine at Mount Sinai The Mount Sinai Hospital, New York, NY COI Research
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationHyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine
Hyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine The new england journal of medicine Original Article Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationCharacterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER
Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia
More informationWorkshop. Todd Anderson MD / Jacques Genest MD
Workshop Todd Anderson MD / Jacques Genest MD Game-Changing Trials 2017 FOURIER Evolocumab n=27,564 HR 0.80 CANTOS Canakinumab n=10,061 HR 0.85 COMPASS Rivaroxaban + ASA n=27,395 HR 0.76 Key Secondary
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationNew Approaches to Lower LDL-C
New Approaches to Lower LDL-C CSIM 27 October 2016 Jacques Genest MD Cardiovascular Health Across the Lifespan Program McGill University Health Center Disclosure J. Genest MD 2016 Advisory Board, Speaker
More informationCholesterol, guidelines, targets and new medications
Cholesterol, guidelines, targets and new medications Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers Grants/Research
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationDrug Class Review Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors
Drug Class Review Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors Final Original Report July 2015 The purpose of reports is to make available information regarding the comparative clinical
More informationPCSK9 Inhibitors Current Status
PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Fall Conference 2015 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationEVIDENCE TO DATE EVOLOCUMAB (REPATHA)
and Clinical Outcomes in Patients with Cardiovascular Disease, March 2017 1 CLINICAL QUESTION In patients with atherosclerotic cardiovascular disease and LDL >1.8mmol/L or non-hdl > 2.6mmol/L, how does
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationPCSK9 Inhibitors Current Status
PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Spring Conference 2016 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationEvan A. Stein 1, David Sullivan 2, Anders G. Olsson 3, Rob Scott 4, Jae B. Kim 4, Allen Xue 4, Thomas Liu 4, Scott M. Wasserman 4
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo and Ezetimibe Controlled Study Evan A. Stein 1, David Sullivan
More informationPCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy
PCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy Sergio Fazio, MD, PhD William and Sonja Connor Professor of Preventive Cardiology Professor of Medicine, Physiology & Pharmacology Director, Center for
More informationPCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia
: 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationPCSK9 Inhibitors: A View of Clinical Studies
PCSK9 Inhibitors: A View of Clinical Studies Slide deck kindly donated for website use by Professor Raul D. Santos Lipid Clinic InCor-HCFMUSP Sao Paulo, Brazil PCSK9 Inhibitors : A View of Clinical Studies
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationChanging Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events
Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events Deepak L. Bhatt, MD, MPH Executive Director Interventional Cardiovascular Programs Brigham and Women s Hospital
More informationEfficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies
Efficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies Michael J. Koren, 1 Evan A. Stein, 2 Eli M. Roth, 3 James M. McKenney, 4 Dan Gipe,
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informatione Corrado Tamburino, MD, PhD
Transcatheter Aortic Valve Implantation Stroke: etiology ogy and prevention e Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationDoes COMPASS Change Practice?
Does COMPASS Change Practice? C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division Chairman, PERFUSE Study Group Founder,
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationAccumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges
ESC 2015 London Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges Paul M Ridker, MD, MPH Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationTRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital
TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationRe- Setting our COMPASS for Secondary Prevention in Atherosclerotic Vascular Disease
Re- Setting our COMPASS for Secondary Prevention in Atherosclerotic Vascular Disease Robert C. Welsh, MD, FRCPC Professor of Medicine, University of Alberta Zone Clinical Department Head, Cardiac Sciences
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationShould We Reconsider using Anticoagulation for Biological Tissue Valves
Should We Reconsider using Anticoagulation for Biological Tissue Valves No Disclosures Disclosures Watching grass grow Complete with audio 1 hour 8 minutes 9884 views Subclinical Leaflet Thrombosis in
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationThrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs
Thrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs David J. Moliterno, MD Professor and Chairman Department of Internal Medicine The University of Kentucky Linda and Jack Gill Heart Institute
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationEducational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality
Educational Objectives At the conclusion of this activity, participants should be able to: Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements
More informationPCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials?
PCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials? Slide deck kindly supplied as an educational resource by Dr Evan A Stein MD PhD Director Emeritus Metabolic & Atherosclerosis
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationThe Korean Society of Cardiology COI Disclosure
The Korean Society of Cardiology COI Disclosure Name of First Author: Yongwhi Park The authors have no financial conflicts of interest to disclose concerning the presentation 2017 Annual Spring Scientific
More informationAntisense and Antibodies as Game changers in refractory dyslipidemia. Erik Stroes AMC
Antisense and Antibodies as Game changers in refractory dyslipidemia Erik Stroes AMC Asymptomatic phase Plaque rupture There is a significant residual CVD risk at least partially modifiable Postponement
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationLandmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549
2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationWHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.
TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot
More information